MedTherapy Biotechnology Aims to Make CAR-T Cell Cancer Gene Therapy More Affordable

Strategic Insights -

MedTherapy Biotechnology, a privately held CAR-T cell cancer gene therapy biotechnology company, has announced that its technology could potentially reduce the time and cost to manufacture CAR-T cell cancer gene therapy to a fraction, approximately by seventy percent. The company's clinical development plan and strategies are being presented at the BIOTECH SHOWCASE conference being held during the JPMorgan Chase Healthcare Conference in San Francisco, CA. According to CEO Bikash Verma, MD, DVM, MedTherapy's mission is to make the exorbitantly expensive CAR-T cell cancer gene therapy more affordable and accessible. The company's integrated strategy aims to overcome the current constraints in CAR-T cell therapy, including a long manufacturing process, industry-wide lack of capacity, acute shortage of critical raw materials, and patients relapsing after treatment.

Key Takeaways:

  • MedTherapy Biotechnology's technology could potentially reduce the time and cost to manufacture CAR-T cell cancer gene therapy by approximately seventy percent.
  • The company has developed an integrated approach to overcome the current constraints in CAR-T cell therapy, including a long manufacturing process, industry-wide lack of capacity, acute shortage of critical raw materials, and patients relapsing after treatment.
  • MedTherapy's strategies include developing next-generation CAR-T therapy candidates, a global GMP-grade commercial manufacturing facility with cost- and time-efficient technologies, and next-generation virus vector technology and facilities for large-scale industry-level manufacturing of viral vectors.
  • The company's technology aims to manufacture CAR-T cells in a few days instead of the industry average of four to six weeks.
  • MedTherapy's integrated approach will lead to dramatic reductions in the cost and time to manufacture CAR-T cell gene therapy.

Statistics:

  • MedTherapy's technology could potentially reduce the cost to manufacture CAR-T cell gene therapy by approximately seventy percent.
  • The company is aiming to manufacture CAR-T cells in a few days instead of the industry average of four to six weeks.
  • MedTherapy has built a global commercial manufacturing facility deploying next-generation technology.
  • The company has also built an industry-scale virus vector manufacturing facility with increased transfection and transduction capacities.

Sources:

  • MedTherapy Biotechnology news release, January 23, 2023
  • Cancer Gene Therapy Week, January 23, 2023
  • BIOTECH SHOWCASE conference, JPMorgan Chase Healthcare Conference, San Francisco, CA
  • Interview with Dr. Daniel DeAngelo, Chief of the Division of Leukemia, Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School